Last updated on October 2018

Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Brief description of study

This is a clinical study where patients with diabetes and a vision threatening eye condition called "Diabetic Macular Edema" receive four injections into the eye at monthly intervals. The patients will already have tried the standard of care without complete success. The patients will be randomized to receive either a high dose, a low dose or a sham control treatment. The study will evaluate whether the new treatment improves vision and whether it changes the underlying course of the disease in the eye.

Clinical Study Identifier: NCT03466099

Contact Investigators or Research Sites near you

Start Over

KalVista Pharmaceuticals

KalVista Investigative Site
Tucson, AZ United States
  Connect »